Clinical Trial Detail

NCT ID NCT01274624
Title Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Oncolytics Biotech
Indications

colon cancer

rectum cancer

Therapies

FOLFIRI

Bevacizumab + Reolysin

Age Groups: adult

Additional content available in CKB BOOST